Michael F. Ackermann

Michael Ackermann, PhD, MBA is a recognized transformational business leader with an outstanding record of success in strategic and operational assignments in pharmaceutical development and commercialization. He has more than 30 years of executive management experience and has led the successful launch of major pharmaceutical products, while building and developing teams to improve the performance of multiple organizations. His expertise includes developing and implementing product and commercial strategies, building high performance teams, improving organizational performance and efficiency, launching products successfully in competitive markets, and building a systematic product development approach achieving crossfunctional integration.

Mike is currently the co-Founder, COO and Business Development lead for Arrivo BioVentures, LLC, an early phase clinical development company, founder of Magnatas, LLC supporting start-up healthcare companies and venture firms. In addition, he is the co-founder and president of AB Collaborative Investments, an Angel Investment firm, which focuses on local and regional healthcare and IT start-ups. He recently joined Solas BioVentures as a Managing Director of Business Development helping Solas building investment portfolios.

Previously, Mike worked for several years at Quintiles Transnational as senior vice president for global commercial solutions, where he developed comprehensive customer solutions to support clients from phase I/II through launch, generating $100 million in net new business. In this role, he led the Medical Communications Division of Quintiles through an organizational, operational and skill upgrade. He achieved record new business and revenue, significantly improving profitability and efficiency. Collaborating with the Quintiles product development team, he initiated the Integrated Asset Development Plan to align clinical and commercial insights during the product development phase.

Prior to Quintiles, Mike spent more than 18 years at Eli Lilly and Company where he served as the President of the US Neuroscience Business Unit. He led the unit’s performance improvement and led the launch of Strattera (ADHD) and Cymbalta (Depression). In addition, he held leadership positions in Market Research, Global and US Pricing, Sales, and Global Health Outcomes to support Lilly’s strategic and operational initiatives.

Mike holds a BS degree in biology from Hampden-Sydney College in Virginia, a PhD in immunology from the Drexel University College of Medicine, and an MBA from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill. In addition, he served as the Fogarty International Post-doctoral Fellow at the National Institutes of Health/NIEHS.